CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...
Phase 3
Marietta, Georgia, United States and 250 other locations
The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in mea ...
Phase 2
Atlanta, Georgia, United States and 31 other locations
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...
Phase 1, Phase 2
Atlanta, Georgia, United States and 83 other locations
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor...
Phase 2, Phase 3
Atlanta, Georgia, United States and 878 other locations
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody ta...
Phase 1
Atlanta, Georgia, United States and 18 other locations
plus BSC in participants with refractory metastatic colorectal cancer (mCRC). 691 participants were randomized to one of the following treat...
Phase 3
Atlanta, Georgia, United States and 152 other locations
\[Amph-Peptides 7P\]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtain...
Phase 1, Phase 2
Atlanta, Georgia, United States and 27 other locations
evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors...
Phase 1, Phase 2
Austell, Georgia, United States and 219 other locations
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab ver...
Phase 3
Atlanta, Georgia, United States and 282 other locations
a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon...
Phase 3
Atlanta, Georgia, United States and 989 other locations
Clinical trials
Research sites
Resources
Legal